{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.7","upperLimit":"53.5","value":"35"},{"groupId":"OG001","lowerLimit":"31.9","upperLimit":"65.6","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is defined as \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.","dispersionType":"95% Confidence Interval","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 253 weeks","title":"CE Phase: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}